Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03347838 · ClinicalTrials.gov registry record · Phase 2
Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers
A Phase 2 study of Tobacco Smoking and Bronchial Dysplasia, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT03347838 is a Phase 2 study of Tobacco Smoking and Bronchial Dysplasia that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 19 participants, below the 477-participant average among 38 other Tobacco Smoking trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03347838, a Phase 2 study of Tobacco Smoking and Bronchial Dysplasia, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical research study is to determine whether the PD-1 inhibitor (Programmed cell death protein 1) nivolumab improves premalignant bronchial dysplastic lesions in subjects that are at high risk for the development of lung cancer, including those with a prior smoking history, or history of lung cancer or head and neck cancer. The safety and tolerability of nivolumab will also be studied.
Conditions Studied
Interventions
- DRUG Nivolumab
Study Locations (2)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
- Denver VA Hospital - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-01-30 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03347838
The ClinicalTrials.gov registry entry for NCT03347838 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 477-participant average among 38 other Tobacco Smoking trials with a reported enrollment target (96% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Tobacco Smoking appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT03347838 reports 2 study locations spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03347838 about?
NCT03347838 is a clinical study titled "Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers". The goal of this clinical research study is to determine whether the PD-1 inhibitor (Programmed cell death protein 1) nivolumab improves premalignant bronchial dysplastic lesions in subjects that are at high risk for the development of lung cancer, including those with a prior smoking history, or hi...
What is the current status of trial NCT03347838?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2019-01-30. Estimated completion is 2026-12-31.
What conditions does trial NCT03347838 study?
This clinical trial studies the following conditions: Tobacco Smoking, Bronchial Dysplasia, History of Non-Small Cell Lung Cancer, History of Head and Neck Cancer.
What interventions are being tested in trial NCT03347838?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT03347838?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03347838 being conducted?
This trial has 2 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cannabidiol for Reducing Cigarette Use
RECRUITING · Phase 2
-
Intervention to Increase Intention to Change Alcohol/Tobacco Use in Veterans With Chronic Disease
RECRUITING · Phase 3
-
Effects of Cannabidiol on Stress and Nicotine Withdrawal
RECRUITING · Phase 1
-
Reach Through Equitable Implementation in Utah
RECRUITING · NA
-
The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study
RECRUITING
-
Development of a Smoking Cessation Video Series
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.